focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.
Fml what are you talking about 19p
In a sea of worthless arguments and valid confusion, this post is refreshing to read. Crucial we hear from the company about their next steps - as you said, I'd imagine they have a contingency plan.
I am in a very similar situation, almost feels like betrayal. To be clear, as someone from a science background, the science does check out and I believe that on it's own it should work - I do not know what happened with the trial, I threw out all of the trading fundamentals to back the company behind this drug. The last bullet in the chamber is Activ2.
Like you and many others here, I did this trying to improve my life and the lives of everyone around me - nothing but respect to the usuals here.
I've been having a lot of luck with SOARE recently.
This is a great spot, thanks for posting.
Shame on everyone deliberately causing disruption in here, it's drivel but I hope that newer investors don't take it seriously. Despite the relentless and pointless howling, I haven't seen anyone disproving the science of interferon yet so until you can, the rest of us invested aren't interested.
To the LTHs tirelessly posting valuable comments and support (you all know who you are), thank you for always holding the fort.
Not long now, GLA.
All the best, bennitto. Whether you have 1k, 11k, or 111k, we're all on the same ship.
GL to us all!
I find myself having this reaction quite a lot these days.
@Doc "Omicron isn’t as severe as Delta." - this is spreading misinformation. If you have data to back this up please do so, otherwise it would irresponsible to keep pushing this quote.
If you have conducted your own study that hasn't been made available to the public yet, please publish asap.
Thinking it's peaked will spin this situation even more out of control than it already is. We're seeing new problems such as testing capacity being hit which is rather crazy to think about.
The actual number of cases are higher than what we're seeing even before Christmas, let that sink in.
Oldbaldy right there with you, the original reasons for investment here are the staple thing that will keep you sleeping soundly. Things are aligning well, and given the timings of upcoming unblinded data, the recent interview with SSH, along with an upcoming one with RM, I agree that we're close to being where we imagined ourselves long ago.
All the LTHs have done incredibly well, not long to go at all. GLA.
Great thread Peelweight, hopefully puts the "mild" army to rest.
The "mild" argument is pretty weak, not to mention insensitive towards the actual staggering increase in hospitalisations in places like SA.
The "why hasn't it been tested on X variant" is also weak, because the virus is mechanistically the same regardless of variant - I understand some people aren't clued up on the science but that's basic biology.
All of us LTHs have seen these games played throughout this journey we've shared together, and with certain shorters involved and large IIs, it's pretty clear something large is on the horizon. If staring at the SP shakes you, put it away and read the papers that got you invested here in the first place.
@Ndn that's also my concern, that after the price surge it'll be difficult to sell - but as you said, it's about what happens in the moment and/or price limit.
LiveLif - you said it yourself, it's more transmissible. Through being in the pandemic for this long, how do you not yet understand that it's the transmissibility that causes the damage? Going back to the basics here... The more transmissible a virus, the more potential for it to reach more of the population (bonus points for figuring out that this means reaching potentially older and younger people), couple this with the increasing data about reinfection and spreading within vaccinated individuals and you have a rather significant problem on your hands.
"and more reports out of South Africa suggest the new Omicron variant is not more lethal than the previous Delta variant." - You're riding on a quote that was taken out of context, please do more research and look at more data (we don't have much yet) on Omnicron before saying such unfounded and dangerous things, we won't know this for a while but the data so far suggests hospitalisations shooting up in certain areas.
This is probably being thought of by many people here, but I'll say it anyway: This is one of the best articles we've ever had about Synairgen, and it's what we were imagining once the stars aligned.
Wonder drug indeed.
Kiwi, mact, and anyone else who has been forced to sell at all or have any concerns - don't worry, it happens. You have shown bulletproof mindsets when it comes to remaining level-headed and continuing to offer valuable posts through the highs and lows, which is in stark contrast to others who flip the switch between ramping and de-ramping when it best suits their interests.
No one could have foreseen a slight delay, but I have never been more confident that we'll all be rewarded because of the data so far, the ever-increasing literature in support of the science (which by the way none of the other treatments so far have), and objectives that the company is both hitting and forecasting for the near future.
"Maximising shareholder value" is in their best interests, and those are words from RM himself.
I believe this thread will be one to keep coming back to over the coming months, my mind has been fixated on how much damage corticosteroids can do in those situations, and how globally huge an anti-viral will be when it comes to the next wave. Whenever the waters become turbulent, I hope everyone can return here until they're smooth again.
Great point Sharedealer. If anyone does not understand why ÂŁ2k/ÂŁ3k per treatment is viable at this point, I recommend looking at the ongoing global hospitalisations. On the back of that, have a think about the uncertainty people experience when they contract Covid, this level of uncertainty increases as symptoms progress. Now think about whether cost would really be an issue if it meant life or death.
There are enough variants to demonstrate exactly why the "size of the market" still holds up. The new variant spreading from South America that PHE reported on, B.1.621, was designated a VUI - low number of cases for this in the UK yes, but that's how they all start out. It's possibly rather vaccine resistant, and it's just the beginning of the vax resistant models because that's how viruses work.
Does anyone honestly think that governments wouldn't stock a variant-agnostic treatment to both prepare for this, and treat the current patients still ending up in hospital?
One final point: Winter is coming.
SeaBoy, this was an excellent thread - thank you for providing such detailed insights from the front of the ship! This one will go down in history and no doubt will make its way to RM's eyes. The ship now sails smoother and we're ready to welcome SNG001.
Part of the ship, part of the crew!